

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Life360, Inc.</b>
<b>ARBN: 629 412 942</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Christopher (Chris) Hulls
<b>Date of last notice</b>	16 June 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct Interest
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-
<b>Date of change</b>	20 May 2022
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>• 5,059,656 CHESSE Depository Interests (CDIs)</li> <li>• 1,241,281 Shares of Common Stock (<b>Shares</b>)(equivalent to 3,723,843 CDIs)</li> <li>• 2,012,956 Options over Shares (<b>Options</b>)</li> <li>• 103,596 Restricted Stock Units (<b>RSUs</b>)</li> <li>• 89,880 CDIs held by ICCA Labs, LLC<sup>1</sup></li> </ul>
<b>Class</b>	Options

<sup>1</sup> Chris Hulls is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of CDIs attributable to Chris Hulls by reason of his membership interest in ICCA Labs, LLC is 89,880.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Number acquired</b>	77,392 <sup>2</sup>
<b>Number disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Options are granted for no consideration. Each option has an exercise price of US\$8.19.
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>• 5,059,656 CDIs</li> <li>• 1,241,281 Shares (equivalent to 3,723,843 CDIs)</li> <li>• 2,090,348 Options</li> <li>• 103,596 RSUs</li> <li>• 89,880 CDIs held by ICCA Labs, LLC</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of additional options approved by shareholders at the 2022 AGM following a calculation error which understated the number of options granted (and notified) by 77,392 options <sup>2</sup> .

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

<sup>2</sup> This Appendix 3Y updates the Appendix 3Y lodged with the ASX on 27 May 2022 whereby the actual number of options granted is 281,965 (being the 204,573 options set out in the Appendix 3Y lodged on 27 May 2022 together with the 77,392 options the subject of this Appendix 3Y).

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.